We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
- Authors
Ingram, Wendy; Devereux, Stephen; Das-Gupta, Emma P.; Russell, Nigel H.; Haynes, Andrew P.; Byrne, Jennifer L.; Shaw, Bronwen E.; McMillan, Andrew; Gonzalez, Juan; Ho, Aloysius; Mufti, Ghulam J.; Pagliuca, Antonio
- Abstract
The role of haematopoietic stem cell transplantation (HSCT) in relapsed follicular lymphoma remains controversial. This study analysed 126 patients with relapsed, advanced stage follicular lymphoma who received BEAM (BCNU [carmustine], cytarabine, etoposide, melphalan)-alemtuzumab allogeneic HSCT (BEAM-allo) ( n = 44) or BEAM-autologous HSCT (BEAM-auto) ( n = 82). The BEAM-allo group had a younger median age (48 years vs. 56 years, P < 0·001) but received a higher median number of therapies pretransplant ( P = 0·015) compared with the BEAM-auto group. There was a higher non-relapse mortality (NRM) in the BEAM-allo group compared with the BEAM-auto group at 1 year (20% vs. 2%, P = 0·001). Older age and heavily pretreated patients were associated with a higher NRM and poorer survival in the BEAM-allo group. There was, however, a significantly lower relapse rate (20% vs. 43%, P = 0·01) at 3 years with BEAM-alemtuzumab, with no relapses after 2 years, compared with a continued pattern of relapse in the autologous group. No difference in overall survival (OS) ( P = 0·99) or disease-free survival (DFS) ( P = 0·90) was identified at 3 years, whereas a plateau in OS and DFS with crossing of the survival curves in favour of BEAM-allo group was observed. Furthermore, the ability to re-induce remissions with donor leucocytes provides additional benefit in favour of allogeneic HSCT.
- Subjects
LYMPHOMAS; STEM cell transplantation; HEMATOPOIETIC stem cells; ANTINEOPLASTIC agents; TRANSPLANTATION of organs, tissues, etc.; BONE marrow cells
- Publication
British Journal of Haematology, 2008, Vol 141, Issue 2, p235
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/j.1365-2141.2008.07067.x